Calciphylaxis: A successful outcome whilst on peritoneal dialysis

  • Ana Gaspar Hospital Prof. Doutor Fernando Fonseca
  • Luis Falcão Department of Nephrology of Hospital Beatriz Ângelo, Loures, Portugal
  • Sofia Correia Peritoneal Dialysis Unit, Centro Hospitalar e Universitário do Porto, Portugal.
  • Maria João Carvalho Peritoneal Dialysis Unit, Centro Hospitalar e Universitário do Porto, Portugal.
  • Anabela Rodrigues Peritoneal Dialysis Unit, Centro Hospitalar e Universitário do Porto, Portugal.
  • Antonio Cabrita Peritoneal Dialysis Unit, Centro Hospitalar e Universitário do Porto, Portugal.
Keywords: calciphylaxis, hyperpabic oxygen, peritoneal dialysis, sodium thiosulfate

Abstract

Calciphylaxis is a life threatening disease for which patients with chronic kidney disease, particular those on dialysis, are at increased risk. As it is a rare condition, treatment options are limited and duration of treatment is not clear, especially when it comes to patients on renal replacement treatment with peritoneal dialysis.

We report a case of a 55 year-old woman with end stage renal disease on renal replacement treatment with peritoneal dialysis for five months that presented with severe calciphylaxis of both legs. She had started haemodialysis at the age of 31 and 3 later she received a cadaveric renal transplant that lasted for 20 years. She was treated with warfarin due to atrial fibrillation diagnosis. The treatment approach was multimodal and multidisciplinary and included treatment with sodium thiosulfate and hyperbaric oxygen, warfarin suspension and maintenance of optimized peritoneal dialysis prescription. Additionally, wound dressings were done every other day and antibiotics started whenever there were signs of infection and pain was managed with high doses of opiates and pain adjuvants. There was significant improvement and the patient kept peritoneal dialysis treatment with preserved residual renal function.
This raises the question, if there is a need to transition calciphylaxis patients on peritoneal dialysis to haemodialysis, as it is possible to ensure a high efficiency dialysis program with automated peritoneal dialysis.

References

(1) Nigwekar SU, Thadhani R, Brandenburg MD. Calciphylaxis. N Engl J Med 2018;378:1704-14.; https://doi.org/10.1056/NEJMra1505292

(2) Udomkarnjananun S, Kongnatthasate K, Praditpornsilpa K, et al. Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-Analysis. Kidney Int Rep 2018. https://doi.org/10.1016/j.ekir.2018.10.002

(3) Ellis CL, O´Neill WC. Questionable specificity of histologic findings in calcific uremic arteriolopathy. 2018; 94(2): 390-395. https://doi.org/10.1016/j.kint.2018.03.016

(4) Kalajian AH, Malhotra PS, Callen JP, Parker LP. Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed. Arch Dermatol 2009; 145: 451-8. https://doi.org/10.1681/ASN.2015091065

(5) Vanparys J, Sprangers B, Sagaert X, Kuypers DR. Chronic wounds in a kidney transplant recipient with moderate renal impairment. Acta Clin Belg 2013; 68: 128-31. https://doi.org/10.2143/acb.3191

(6) Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol 2016; 27: 3421-9. https://doi.org/10.1681/ASN.2015091065

(7) McCarthy JT, El-Azhary RA, Patzelt MT, et al. Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. Mayo Clin Proc 2016; 91: 1384-94. https://doi.org/10.1016/j.mayocp.2016.06.025

(8) Brandenburg VM, Kramann R, Rothe H, et al. Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant 2017; 32: 126-32. https://doi.org/10.1093/ndt/gfv438

(9) 4. Brandenburg VM, Evenepoel P, Floege J, et al. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis? Nephrol Dial Transplant 2016; 31: 1211-9. https://doi.org/10.1093/ndt/gfw025

(10) Zhang Y, Corapi KM, Luongo M, Thadhani R, Nigwekar SU. Calciphylaxis in peritoneal dialysis patients: a single center cohort study. Int J Nephrol Renovasc Dis 2016; 9: 235-41. https://doi.org/10.2147/IJNRD.S115701

(11) Heaf JG. Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient. Perit Dial Int 2015; 35(6):640-4. http://doi.org/10.3747/pdi.2014.00339

(12) Wang AY .Calcium Balance and Negative Impact of Calcium Load in Peritoneal Dialysis Patients. Perit Dial Int. 2014;34(4):345-52. http://doi.org/10.3747/pdi.2013.00177

(13) Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J Nephrol. 2011;24(2):142–148. https://doi.org/10.5301/JN.2011.6366

(14) Nicholas J, Evans R, Shaw C, et alc.UK Renal Registry 18th Annual Report: Chapter 9 Biochemical Variables amongst UK Adult Dialysis Patients in 2014: National and Centre-specific Analyses. Nephron. 2016;132 Suppl 1:195-236. https://doi.org/10.1159/000444823

(15) Kuhlmman MK. Phosphate Elimination in Modalities of Hemodialysis and Peritoneal Dialysis. Blood Purif. 2010;29(2):137-44. http://doi.org/10.1159/000245640

(16) Zitt E, König M, Vychytil A, et al. Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant 2013; 28: 1232-40. https://doi.org/10.1093/ndt/gfs548

(17) Baldwin C, Farah M, Leung M, et al. Multi-intervention management of calciphylaxis: a report of 7 cases. Am J Kidney Dis 2011; 58: 988-91. https://doi.org/10.1053/j.ajkd.2011.06.002

(18) Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 2013; 8: 1162-70. https://doi.org/10.2215/CJN.09880912

(19) Singh RP, Derendorf H, Ross EA. Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol 2011; 6: 11559. https://doi.org/10.2215/CJN.09671010

(20) An J, Devaney B, Ooi KY, Ford S, Frawley G, Menahem S. Hyperbaric oxygen in the treatment of calciphylaxis: a case series and literature review. Nephrology (Carlton) 2015; 20: 444-50. https://doi.org/10.1111/nep.12433

(21) King BJ, El-Azhary RA, McEvoy MT, et al. Direct oral anticoagulant medications in calciphylaxis. Int J Dermatol 2017;56:1065-70. https://doi.org/10.1111/ijd.13685

(22) Bouderlique E, Provot F, Lionet A. Rheopheresis for Adjuvant Treatment in Resistant Calciphylaxis. Ther Apher Dial 2018;22(4):413-414. https://doi.org/10.1111/1744-9987.12666

(23) Brandenburg VM, Sinha S, Terregrosa JV, et al. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF 472 treatment: a phase 2 open-lable study of patients with calciphylaxis. J Nephrol 2019;32(5):811-822. https://doi.org/10.1007/s40620-019-00631-0

Published
2019-12-15